Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

NCT03189836 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Lymphoma

Interventions

BIOLOGICAL: ACTR707
BIOLOGICAL: rituximab

Sponsor

Cogent Biosciences, Inc.